--- schema_version: "secwatch.filing_event.v1" accession: "0001558370-23-011550" form_type: "8-K" ticker: "PLX" cik: "0001006281" company_name: "Protalix BioTherapeutics, Inc." filed_at: "2023-06-29T23:59:59+00:00" generated_at: "2026-06-13T14:34:29.673917+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.5 calibrated_materiality_score: 0.15 confidence: "high" source: SEC EDGAR --- # Protalix adjourns annual meeting to solicit votes for authorized share increase to 185M ## Summary - Meeting approved election of 7 directors; votes ranged from 30.1M to 30.7M for, 2.2M to 2.7M withheld. - Stock plan amendment approved: shares available increased from 8.475M to 12.475M (25.8M for, 6.9M against). - Advisory vote on say-on-pay frequency favored one year (30.3M votes); board adopts annual frequency. - Meeting adjourned to July 13, 2023 to solicit more votes for charter amendment increasing authorized shares from 144M to 185M. - Ratification of PwC as auditor approved with 36.8M for, 2.7M against; broker non-votes existed on other items. ## SEC filing metadata - accession: 0001558370-23-011550 - form_type: 8-K - ticker: PLX - cik: 0001006281 - company_name: Protalix BioTherapeutics, Inc. - filed_at: 2023-06-29T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.5 - calibrated_materiality_score: 0.15 - confidence: high - sec_items: 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837023011550/0001558370-23-011550-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837023011550/plx-20230628x8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001558370-23-011550 - JSON: https://secwatch.observer/filing/0001558370-23-011550.json - Plain text: https://secwatch.observer/filing/0001558370-23-011550.txt ## Key facts - Shareholder Votes Protalix BioTherapeutics, Inc. shareholders approved Adoption of amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of common stock available under the plan from 8,475,171 shares to 12,475,171 shares and to amend certain other terms of said plan at the 2023-06-28 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2023-06-28 source text: (4) Adoption of amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of common stock available under the plan from 8,475,171 shares to 12,475,171 shares and to amend certain other terms of said plan ​ For ​ Against ​ Abstain Broker Non-Votes 25,811,597 6,921,213 108,665 8,872,021 evidence_url: https://www.sec.gov/Archives/edgar/data/1006281/000155837023011550/0001558370-23-011550-index.htm - Shareholder Votes Protalix BioTherapeutics, Inc. shareholders approved Approval, on a non-binding advisory basis, the frequency (every one, two or three years) that stockholders of the Company will have a non-binding, advisory vote on the compensation of the Company’s named executive officers at the 2023-06-28 meeting. - Proposal: say on pay frequency - Outcome: passed - Meeting: 2023-06-28 source text: (3) Approval, on a non-binding advisory basis, the frequency (every one, two or three years) that stockholders of the Company will have a non-binding, advisory vote on the compensation of the Company’s named executive officers ​ ​ One Year ​ Two Years ​ Three Years ​ Abstain Broker Non-Votes 30,261,982 600,162 825,319 1,154,012 8,872,021 evidence_url: https://www.sec.gov/Archives/edgar/data/1006281/000155837023011550/0001558370-23-011550-index.htm - Shareholder Votes Protalix BioTherapeutics, Inc. shareholders approved Approval, on a non-binding, advisory basis, the compensation of the Company’s named executive officers at the 2023-06-28 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2023-06-28 source text: (2) Approval, on a non-binding, advisory basis, the compensation of the Company’s named executive officers ​ For ​ Against ​ Abstain Broker Non-Votes 26,186,630 4,269,510 491,310 8,872,021 evidence_url: https://www.sec.gov/Archives/edgar/data/1006281/000155837023011550/0001558370-23-011550-index.htm - Shareholder Votes Protalix BioTherapeutics, Inc. shareholders approved Election of Directors at the 2023-06-28 meeting. - Proposal: director election - Outcome: passed - Meeting: 2023-06-28 source text: (1) Election of Directors ​ For ​ Withheld Broker Non-Votes Zeev Bronfeld 30,118,208 2,723,267 8,872,021 Dror Bashan 30,175,739 2,665,736 8,872,021 Amos Bar Shalev 30,118,524 2,722,951 8,872,021 Shmuel “Muli” Ben Zvi, Ph.D. 30,614,690 2,226,785 8,872,021 Pol F. Boudes, M.D. 30,619,760 2,221,715 8,872,021 Gwen A. Melincoff 30,517,556 2,323,919 8,872,021 Aharon Schwartz, Ph.D. 30,659,904 2,181,571 8,872,021 evidence_url: https://www.sec.gov/Archives/edgar/data/1006281/000155837023011550/0001558370-23-011550-index.htm - Shareholder Votes Protalix BioTherapeutics, Inc. shareholders approved Approval of adjournment of the 2023 Annual Meeting to July 13, 2023 to provide additional time to solicit proxies for a charter amendment at the 2023-06-28 meeting. - Proposal: charter amendment - Outcome: passed - Meeting: 2023-06-28 source text: The adjournment was approved by a vote of 39,819,471 shares of Common Stock, with no shares voting against the adjournment or abstaining evidence_url: https://www.sec.gov/Archives/edgar/data/1006281/000155837023011550/0001558370-23-011550-index.htm - Shareholder Votes Protalix BioTherapeutics, Inc. shareholders approved Ratification of the appointment of Kesselman & Kesselman, Certified Public Accountant (Isr.), a Member of PricewaterhouseCoopers International Limited, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-28 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-06-28 source text: (5) Ratification of the appointment of Kesselman & Kesselman, Certified Public Accountant (Isr.), a Member of PricewaterhouseCoopers International Limited For Against Abstain 36,781,844 2,683,094 354,533 evidence_url: https://www.sec.gov/Archives/edgar/data/1006281/000155837023011550/0001558370-23-011550-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.